# US 2025/0149178 A1 · Identifying non-disease patients using a disease related assay and analysis in the liquid biopsy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0149178 A1
- Document ID: US20250149178A1
- Status: Published application
- Kind: A1
- Application number: 18/833,524
- Filed: 2023-01-30
- Published: 2025-05-08
- Earliest claimed: 2022-01-28
- Assignees: University of Southern California
- Applicants: University of Southern California
- Inventors: Peter KUHN; Anand Ratnakar KOLATKAR; Rafael NEVAREZ; Nicholas MATSUMOTO; Jeremy Michael MASON; Stephanie Nicole SHISHIDO
- Web page: https://patentgrep.com/patent/US20250149178A1

## CPC

- G16H 50/30: for calculating health indices; for individual health risk assessment
- G01N 21/6458: {Fluorescence microscopy (fluorescence microscopes per se G02B21/0076 and G02B21/16)}
- G01N 33/537: with separation of immune complex from unbound antigen or antibody
- G06T 7/0012: {Biomedical image inspection}
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 40/63: for local operation
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G06T 2207/10056: Microscopic image
- G06T 2207/10064: Fluorescence image
- G06T 2207/30024: Cell structures in vitro; Tissue sections in vitro
- G06T 2207/30096: Tumor; Lesion
- G16H 10/60: for patient-specific data, e.g. for electronic patient records
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G06T: IMAGE DATA PROCESSING OR GENERATION, IN GENERAL

## Abstract

An imaging structure identification system includes an optical imaging system configured to illuminate a liquid biopsy sample for a subject. The liquid biopsy sample has one or more biological structures that are labeled with one or more fluorophores associated with a fluorescence assay for a disease state allowing detection of emitted electromagnetic radiation from the liquid biopsy sample as image data. The system also includes a processing system configured to identifying the subject as being at reduced risk for having the disease state if the subject profile is similar to the first predetermined profile for subjects not being in the disease state. However, if the subject profile is not similar to the first predetermined profile for subjects not being in the disease state it is not determinative if the subject is in the disease state.

## Claims

### Claim 1

An imaging structure identification system comprising:
an optical imaging system configured to illuminate a liquid biopsy sample for a subject, the liquid biopsy sample having one or more biological structures that are labeled with one or more fluorophores associated with a fluorescence assay for a disease state allowing detection of emitted electromagnetic radiation from the liquid biopsy sample as image data; and
a processing system configured to:
generate images of the one or more biological structures for the subject from the image data, detect and determine a plurality of features from the images or the image data, and form biological structure identification buckets from the plurality of features, each biological structure identification bucket identifying imaging structures that are similar in type;
generate a subject profile of biological structure identification buckets for rare imaging events for the subject;
compare the subject profile with a first predetermined profile for subjects not having the disease state; and
identifying the subject as being at reduced risk for having the disease state if the subject profile is similar to the first predetermined profile for subjects not being in the disease state, wherein if the subject profile is not similar to the first predetermined profile for subjects not being in the disease state it is not determinative if the subject is in the disease state.

### Claim 2 (depends on 1)

The imaging structure identification system of claim 1, wherein the rare imaging events include rare biological structures.

### Claim 3 (depends on 1)

The imaging structure identification system of claim 1, wherein the one or more biological structures include simultaneously identified multiple biological structures.

### Claim 4 (depends on 1)

The imaging structure identification system of claim 1, wherein the optical imaging system includes:
a liquid biopsy sample carrier suitable for receiving and supporting the liquid biopsy sample;
an illumination system capable of illuminating the liquid biopsy sample at a specific wavelength or wavelengths that can be absorbed by the one or more fluorophores;
a light detection system configured to detect and determine an intensity and a wavelength of fluorescence emitted by the one or more fluorophores; and
a light controlling system configured to allow detection of emitted electromagnetic radiation from the liquid biopsy sample; allow detection of electromagnetic radiation scattered by, reflected by, and/or transmitted through the liquid biopsy sample; and guide electromagnetic radiation from the illumination system to the liquid biopsy sample, and from the liquid biopsy sample to the light detection system.

### Claim 5 (depends on 1)

The imaging structure identification system of claim 1, wherein the processing system configured to:
detect and determine morphology of each biological structure using each image; and
identify type of each biological structure from the plurality of features.

### Claim 6 (depends on 1)

The imaging structure identification system of claim 1, wherein at least a subset of the one or more biological structures includes a component selected from the group consisting of a structure with a membrane, a protein, DNA, RNA, and combinations thereof.

### Claim 7 (depends on 1)

The imaging structure identification system of claim 1, wherein at least a subset of the one or more biological structures is a structure with a membrane selected from the group consisting of a cell, a vesicle, and combinations thereof.

### Claim 8 (depends on 1)

The imaging structure identification system of claim 1, wherein the liquid biopsy sample is a non-solid biological sample.

### Claim 9 (depends on 1)

The imaging structure identification system of claim 1, wherein the liquid biopsy sample is a body fluid sample.

### Claim 10 (depends on 1)

The imaging structure identification system of claim 1, wherein the liquid biopsy sample comprises a blood sample, a bone marrow sample, a peritoneal fluid sample, a urine sample, a saliva sample, a vaginal fluid sample, a semen sample, a tear sample, a mucus sample, an aqueous humor sample, a cerebrospinal fluid (CSF) sample, or a combination thereof.

### Claim 11 (depends on 1)

The imaging structure identification system of claim 1, wherein the liquid biopsy sample comprises a blood sample.

### Claim 12 (depends on 1)

The imaging structure identification system of claim 1, wherein the liquid biopsy sample comprises common immune cells and rare biological structures.

### Claim 13 (depends on 1)

The imaging structure identification system of claim 1, wherein the rare biological structures are:
epithelial cells, endothelial cells, mesenchymal cells, other stromal cells, cells that are in various transitional states, or a mixture thereof;
immune cells;
vesicles, or
mixtures thereof.

### Claim 14 (depends on 1)

The imaging structure identification system of claim 1, wherein the liquid biopsy sample comprises common biological structures and rare biological structures such that a total number of biological structures being a sum of the number of common biological structures and rare biological structures, and wherein the rare biological structures are present in an amount equal to or less than 10%, 5%, 1%, 0.1%, or 0.01% of the total number of biological structures.

### Claim 15 (depends on 1)

The imaging structure identification system of claim 1, wherein the emitted electromagnetic radiation is a fluorescent radiation.

### Claim 16 (depends on 1)

The imaging structure identification system of claim 1, wherein the optical imaging system comprises an excitation filter, an emission filter, a (dichroic) mirror, a lens, an optical fiber, or a combination thereof.

### Claim 17 (depends on 1)

The imaging structure identification system of claim 1, wherein the optical imaging system comprises a fluorescence microscope, a brightfield microscope, or a combination thereof.

### Claim 18 (depends on 1)

The imaging structure identification system of claim 1, wherein the processing system comprises a control system, a hardware processor, a memory system, and an information conveying system.

### Claim 19 (depends on 1)

The imaging structure identification system of claim 1, wherein the imaging structure identification system has at least one fluorescence channel.

### Claim 20 (depends on 19)

The imaging structure identification system of claim 19, wherein the imaging structure identification system applies 1 to 10 fluorescence channels.

### Claim 21 (depends on 19)

The imaging structure identification system of claim 19, wherein the imaging structure identification system has 4 to 7 fluorescence channels.

### Claim 22 (depends on 1)

The imaging structure identification system of claim 1, wherein the imaging structure identification system has only four fluorescence channels.

### Claim 23 (depends on 1)

The method of claim 1 wherein the disease state is cancer.

### Claim 24 (depends on 1)

The imaging structure identification system of claim 1, wherein the imaging structure identification system has only four fluorescence channels, wherein the four fluorescence channels are:
a first fluorescence channel configured for detection useful for nuclear segmentation and characterization;
a second fluorescence channel configured to detect a cytokeratin (CK) for its epithelial-like phenotype;
a third fluorescence channel configured to detect a vimentin for its endothelial/mesenchymal-like phenotype; and
a fourth fluorescence channel configured to detect both a CD31 for its endothelial-like phenotype, and a CD45 for its immune cell phenotype.

### Claim 25 (depends on 1)

The imaging structure identification system of claim 1, wherein the imaging structure identification system has only four fluorescence channels, wherein the four fluorescence channels are:
a first fluorescence channel configured for detection of fluorescence emission at a blue color wavelength region;
a second fluorescence channel configured for detection of fluorescence emission at a red color wavelength region;
a third fluorescence channel configured for detection of fluorescence emission at an orange color wavelength region; and
a fourth fluorescence channel configured for detection of fluorescence emission at a green color wavelength region.

### Claim 26 (depends on 25)

The imaging structure identification system of claim 25, wherein the first fluorescence channel is configured to detect 4′,6-diamidino-2-phenylindole (DAPI) for nuclear segmentation and characterization.

### Claim 27 (depends on 25)

The imaging structure identification system of claim 25, wherein the imaging structure identification system has only four fluorescence channels.

### Claim 28 (depends on 27)

The imaging structure identification system of claim 27, wherein the imaging structure identification system has only four fluorescence channels and is configured to identify the endothelial cells and the immune cells from the plurality of features, and to differentiate the endothelial cells from the immune cells, wherein the endothelial cells have more elongated morphologies as compared to the immune cells, and the immune cells have more round morphologies as compared to the endothelial cells.

### Claim 29 (depends on 1)

The imaging structure identification system of claim 1, wherein a biological structure's morphology is determined by using at least one feature from the images or the image data.

### Claim 30 (depends on 1)

The imaging structure identification system of claim 1, wherein a biological structure's morphology is determined from at least 10 features, at least 100 features, at least 500 features, or at least 1,000 features from the images or the image data.

### Claim 31 (depends on 30)

The imaging structure identification system of claim 30, wherein at least a subset of the features are related to size, shape, texture and structure of the one or more biological structures.

### Claim 32 (depends on 1)

The imaging structure identification system of claim 1, wherein the imaging structure identification system further comprises an information conveying system that is configured to convey to a user information related to types of the biological structures present in the liquid biopsy sample, biological structure identification buckets, disease maps, disease atlases, or a combination thereof.

### Claim 33 (depends on 1)

A method for evaluating a subject with the imaging structure identification system of claim 1, the method comprising:
receiving a liquid biopsy sample from a subject comprising biological structures;
preparing a sample comprising a single biological structure layer sample from the liquid biopsy sample, the single biological structure layer sample being a single layer of biological structures;
staining the biological structures of the single layer biological structure sample with a fluorescence assay for a disease state; and
1) analyzing the sample with an imaging structure identification system configured to identify rare biological structures through their fluorescence and morphology and form one or more biological structure identification buckets based on an identified biological structure type, wherein each biological structure identification bucket contains a similar type of biological structures;
generating a subject profile of biological structure identification buckets for rare biological structures for the subject;
comparing the subject profile with a first predetermined profile for subjects not being in the disease state; and
identifying the subject being at reduced risk for being in the disease state if the subject profile is similar to the first predetermined profile for subjects not being in the disease state, wherein if the subject profile is not similar to the first predetermined profile for subjects not being in the disease state it is not determinative for the subject being in the disease state.
